With reproductive rights under attack and professional and personal challenges escalated as a result of the pandemic, women have been collectively called on to lead with not just authenticity, but also with compassion, kindness, and empathy. “In times of crisis, women take center stage. We are the peace makers, the solution seekers, the voice amplifiers,” said HBA interim CEO Wendy White at the 2022 HBA Annual Conference.

We cannot underestimate the negative impact – not only on individual lives but also on wider society – of participant populations not being proportionately represented in clinical trials.

NYF Health launches Future Now Categories, NYF Health DE&I Advisory Board, and Multiple Special Industry Awards.

The company’s expansion into clinical trial recruitment could bring it new streams of revenue from drug companies.

Although artificial intelligence may seem like the great equalizer to humanity’s flawed motivational and cognitive biases, the truth is, even the most advanced AI technologies have biases including race, gender, socioeconomic status, and political identifiers.

The U.S. Equal Employment Opportunity Commission filed a lawsuit Monday against Eli Lilly and Co. alleging the company refused to hire older workers for sales representative positions.

Join hundreds of women and men for this can’t miss event in Philadelphia in November.

About one in four Americans live with some type of disability, according to the CDC, making disabled individuals the largest group of minorities in the country. However, their contributions are remarkedly underreported in the life sciences industry.

Diversity in all clinical research—including rare disease research—is currently under scrutiny, partly because of disparities experienced with COVID-19. Rightly so, as data show that 86 percent of genomics studies to date have involved people of European ancestry, which has limited the potential benefits of genomic research for many populations. Rebecca Sutphen, Co-Founder and Chief Medical Officer of InformedDNA, and Board-Certified Genetic Counselor Karmen Trzupek analyze strategies to increase diversity in rare genetic disease trials.